Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immutep Ltd ( (AU:IMM) ) has shared an announcement.
Immutep announced that an abstract on its lead candidate eftilagimod alfa has been accepted for poster presentation at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago. The study will be presented in the Developmental Therapeutics—Immunotherapy track and examines how eftilagimod alfa, an antigen-presenting cell activator targeting MHC Class II, affects lymphocyte activation and survival in metastatic cancer patients.
The poster will showcase cumulative clinical and translational data indicating that eftilagimod alfa induces rapid, sustained lymphocyte activation and that associated immune markers correlate with improved overall survival across multiple late-stage cancer trials. This visibility at oncology’s largest global forum underscores the potential clinical relevance of the drug’s mechanism of action and may strengthen Immutep’s positioning in the competitive immuno-oncology landscape.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Limited is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a pioneer in LAG-3 biology, leveraging this immune checkpoint to either stimulate or suppress immune responses, and maintains a diversified product portfolio aimed at delivering innovative treatments and enhancing shareholder value.
Average Trading Volume: 28,275,410
Technical Sentiment Signal: Sell
Current Market Cap: A$106.1M
See more data about IMM stock on TipRanks’ Stock Analysis page.